The Pharmaceutical Market: Cuba - 2007 Update a Targeted Report Enabling
You to Keep Up to Date With Market Developments for a Year
DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets
(http://www.researchandmarkets.com/reports/c52599) has announced the
addition of The Pharmaceutical Market: Cuba - 2007 Update from Espicom
Business Intelligence to their offering.
These in-depth pharmaceutical market reports are ideal for executives
wanting to understand the key drivers in pharmaceutical markets and have
access to a wealth of statistical data. Each report opens with an
outlook section that provides analysis of the market, 5-year market
forecasts, national data projections, market outlook and key
developments such as regulation, pricing/reimbursement, intellectual
property, health facilities and government policy. The report also
provides extensive background information, population trends, health
status, health expenditure, organisation & administration, hospital
services, medical personnel, healthcare development, market access
information, trade data for raw materials and finished products and
essential industry contacts. Included with the report are 3 free
quarterly updated outlook reports, enabling you to keep up to date with
market developments for a year.
Content Outline:
1.Introduction
2.Background
3.Population
4.Health Status
5.Health Expenditure
6.Organisation & Administration
7.Hospital Services
8.Out-Patient Care
9.Medical Personnel
10.Pharmaceutical Market Environment
11.Pharmaceutical Market
12.Directory
Cuba is one of the world's last unreconstructed communist countries.
Ruled since the 1950s by Dr Fidel Castro, Cuba has attempted none of the
economic reforms implemented in Eastern Europe or even China. Despite
this, the country has a reputation for the quality of its health
services and health indicators, and has an impressive
pharmaceutical/biotechnology research sector. This reputation is
deserved in part, but conceals an ageing healthcare system in dire need
of restructuring and modernising, none of which can be achieved without
greatly increased funding.
During the Cold War, Cuba was a major Soviet ally, and the market
remained largely closed to the West. During the 1990s, however, many
countries in the West established links with Cuba. The USA, virtually
alone, maintains its embargo against Cuba. This is starting to hurt US
healthcare firms, as companies based in Asia, Canada and Western Europe
have the high-tech market to themselves. The international healthcare
industry is taking an increasing interest in Cuba, which in turn has
made efforts to integrate into the global marketplace in an attempt to
attract new funding for its healthcare system.
Since its realignment under the consortium QUIMEFA in 2001, domestic
pharmaceutical production has kept growing, with increasing
biotechnology export opportunities not only in developing countries but
also in Europe and other developed countries. Cuba maintains a list of
essential medicines (CBM), with 827 in 2005, of which 521 are
domestically produced. There is no commercial advertising in Cuba,
instead advertising has an educational purpose. Cuba affords some level
of pharmaceutical patent protection, although less than international
norms. Since 2001, FARMACUBA has acted as importer, exporter and
distributor for QUIMEFA.
Companies Mentioned:
- Adalberto Pessant
- CIDEM
- CIGB (Heber Biotec)
- CIM (CIMAB)
- Eron
- Instituto FINLAY
- MEDSOL
- Reynaldo Gutierrez
- Roberto Escudero Diaz
- 8 de Marzo
- CancerVax
- Genesis Medical Technologies
- GlaxoSmithKline
For more information visit http://www.researchandmarkets.com/reports/c52599.
No comments:
Post a Comment